CA3075867A1 - Anticorps anti-ramp2 - Google Patents

Anticorps anti-ramp2 Download PDF

Info

Publication number
CA3075867A1
CA3075867A1 CA3075867A CA3075867A CA3075867A1 CA 3075867 A1 CA3075867 A1 CA 3075867A1 CA 3075867 A CA3075867 A CA 3075867A CA 3075867 A CA3075867 A CA 3075867A CA 3075867 A1 CA3075867 A1 CA 3075867A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
antibody
polynucleotide encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3075867A
Other languages
English (en)
Inventor
Takayuki Shindo
Tetsuro Nakamura
Ryu Maeda
Yosuke Nakayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kidswell Bio Corp
Original Assignee
Gene Techno Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Techno Science Co Ltd filed Critical Gene Techno Science Co Ltd
Publication of CA3075867A1 publication Critical patent/CA3075867A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)

Abstract

La présente invention a trait à un anticorps anti-RAMP2 ayant un effet inhibiteur de cAMP et un effet antiprolifératif HUVEC. La présente invention concerne un inhibiteur d'angiogenèse contenant ledit anticorps en tant que principe actif. Particulièrement, la présente invention concerne, dans un test de prolifération in vitro : un anticorps contre une protéine 2 de modification d'activité de récepteur (RAMP2) ayant un effet anti-prolifératif de cellules endothéliales vasculaires, ou des fragments immunoréactifs de ceux-ci; ou un anticorps ayant un effet d'inhibition de la production de cAMP provoquée par des cellules animales par ajout d'adrénomédulline ou de fragments immunoréactifs de celle-ci.
CA3075867A 2017-09-13 2018-09-13 Anticorps anti-ramp2 Abandoned CA3075867A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017-175311 2017-09-13
JP2017175311 2017-09-13
PCT/JP2018/034076 WO2019054460A1 (fr) 2017-09-13 2018-09-13 Anticorps anti-ramp2

Publications (1)

Publication Number Publication Date
CA3075867A1 true CA3075867A1 (fr) 2019-03-21

Family

ID=65722806

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3075867A Abandoned CA3075867A1 (fr) 2017-09-13 2018-09-13 Anticorps anti-ramp2

Country Status (3)

Country Link
JP (2) JP7202011B2 (fr)
CA (1) CA3075867A1 (fr)
WO (1) WO2019054460A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298708A1 (en) * 2002-11-27 2004-06-23 Genpath Pharmaceuticals, Incorporated GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
JP2009504681A (ja) * 2005-08-11 2009-02-05 アミリン・ファーマシューティカルズ，インコーポレイテッド 選択可能な特性を有するハイブリッドポリペプチド
GB0521139D0 (en) * 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
CN101873866B (zh) * 2007-11-26 2013-10-16 独立行政法人科学技术振兴机构 代谢综合症的治疗或预防剂、检查方法、检查药、以及代谢综合症的治疗药的候选化合物的筛选方法
WO2010006168A2 (fr) * 2008-07-09 2010-01-14 University Of Rochester Procédés de traitement du cancer à l'aide d'un agent modulant l'activité du récepteur du peptide lié au gène de la calcitonine (« cgrp »)
FR2934597B1 (fr) * 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
FR2964103B1 (fr) * 2010-08-30 2018-11-23 Universite D'aix-Marseille Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament

Also Published As

Publication number Publication date
JP2022169737A (ja) 2022-11-09
WO2019054460A1 (fr) 2019-03-21
JPWO2019054460A1 (ja) 2020-10-22
JP7202011B2 (ja) 2023-01-11

Similar Documents

Publication Publication Date Title
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
US11472882B2 (en) Anti-B7-H4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
AU2020210142A1 (en) Antagonistic anti-canine PD-1 antibodies
JP5972871B2 (ja) 抗ｉｌ−２３ヘテロ二量体特異的抗体
CA2977621C (fr) Nouvel anticorps se liant a la tfpi et composition le comprenant
US20130273036A1 (en) Fn14 Binding Proteins and Uses Thereof
CN111065652A (zh) 抗4-1bb抗体、其抗原结合片段及其医药用途
TWI790548B (zh) 抗人類cd19抗體
US11746155B2 (en) Cannabinoid receptor type 1 (CB1) binding proteins and uses thereof
US20170129954A1 (en) Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis
CN112243443A (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN111375059A (zh) 一种抗gitr抗体药物组合物及其用途
CN110461874B (zh) 抗gitr抗体、其抗原结合片段及其医药用途
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
CN113227148A (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
US20220332804A1 (en) Complement C2 Binding Proteins and Uses Thereof
CN114437227A (zh) 双特异抗体及其应用
CA3075867A1 (fr) Anticorps anti-ramp2
WO2023125793A1 (fr) Anticorps anti-ccr6 et leurs utilisations
WO2023092048A1 (fr) Anticorps anti-tnf-alpha et compositions
CA3206295A1 (fr) Anticorps anti-sars-cov-2
CN115335402A (zh) 特异性抗原结合分子,其制备方法及医药用途
US20230374149A1 (en) Anti-trop-2 antibody, antigen-binding fragment thereof or mutant thereof, and medical use thereof
CN118108853A (zh) Cd47/4-1bb结合蛋白及其医药用途

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220315

FZDE Discontinued

Effective date: 20220315